Marie Robin, Simona Iacobelli, Linda Koster, Jakob Passweg, Daniele Avenoso, Keith M O Wilson, Urpu Salmenniemi, Peter Dreger, Peter von dem Borne, John A Snowden, Stephen Robinson, Maria Chiara Finazzi, Thomas Schroeder, Matthew Collin, Matthias Eder, Edouard Forcade, Michael Loschi, Stefania Bramanti, Jose Antonio Pérez-Simón, Tomasz Czerw, Nicola Polverelli, Joanna Drozd-Sokolowska, Kavita Raj, Juan Carlos Hernández-Boluda, Donal P McLornan
We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 considered higher dose (HD)). Groups were compared using adjusted Cox models. Cumulative incidences of engraftment and acute GVHD were similar across the 3 groups. The TREO group had significantly better OS than BU-HD (HR:0...
March 15, 2024: Bone Marrow Transplantation